CGBIO’s Post

CG BIO, a headquarter of CG MedTech, announced that significant clinical results demonstrating a 100% interbody fusion success rate at 52 weeks for its innovative bone substitutes "Novosis and Excelos Inject" in the spine surgery have been published in "Journal of Clinical Medicine". The study, led by Prof. Jae-Hwan Cho of Asan Medical Center in Seoul and Prof. Ji-Won Kwon of Severance Hospital in Gangnam, investigated the effectiveness of Novosis in transforaminal lumbar interbody fusion (TLIF) surgery. The product, which contains human recombinant bone morphogenetic protein-2 (rhBMP-2), was shown to significantly increase fusion rates, which is critical to the success of lumbar surgery. We expect that this result will have a positive impact not only on patients but also on the medical environment and society, and we are one step closer to successfully entering the U.S. market, especially since it is a preliminary results of a product similar in composition to Novosis Putty, which is about to enter the U.S. market. Ref. 1. https://lnkd.in/gjUwh7bt Ref. 2. https://lnkd.in/gRvE5DjK #BMP2 #NOVOSIS #NOVOSISPUTTY #BDD #FDA #GSC2024 #CGMEDTECH #CGBIO

Critical medical conditions in combination with life-threatening bleeding in trauma or surgery require effective interventions such as carefully managed coagulation therapy. Yet, evidence and accepted standards in this field remain limited, leading to variable patient outcomes.   To bridge this treatment gap, Octapharma collaborates with leading medical centres across the USA and globally to enhance the understanding and implementation of personalised approaches to manage bleeding.   Explore our efforts in bleeding management and critical care here: https://bit.ly/48QLukI

🔪AngioDynamics gets FDA 510(k) approval for NanoKnife System The NanoKnife System leverages Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without using thermal energy. It delivers high-voltage pulses that create permanent nanopores within the cell membrane, to induce an apoptotic-like cellular death that results in complete ablation of the targeted tissue. According to AngioDynamics, NanoKnife provides an alternative to conventional radical surgery or radiotherapy, which often affects urinary continence and erectile potency. Read more online: https://lnkd.in/gaApQPxY 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

Dear Colleagues, A recent publication in Medical Science Monitor explores the efficacy of percutaneous coronary intervention (PCI) in patients with multi-vessel coronary artery disease (MVD) and moderate/severe ischemic mitral regurgitation (IMR). The study found that PCI could significantly improve MR severity without mitral valve intervention, offering a potential alternative for elderly patients with low body weight and renal insufficiency. These findings highlight the potential of PCI to spare high-risk surgery and alleviate the burden of IMR in specific patient populations. The complete report is now available on the Medical Science Monitor webpage. | https://lnkd.in/dcyW6fPX

Just because Retina World Congress ended doesn’t mean the education does! We are recapping one of the Industry Expert Theaters presented by Maria H Berrocal MD and Dr. Baruch D. Kuppermann titled “A Case-Based Approach to using VABYSMO” #Vabysmo is the first and only FDA-approved treatment designed to block 2 causes of vision loss (VEGF and Ang-2) According to Dr. Berrocal, VABYSMO (faricimab-svoa) unlike Anti-VEGF agents alone, achieves greater drying effects than other agents. In addition, close to 80% of patients in both the #DME and #nAMD patients, we able to be treated every 3-4 months. Listen to this video to hear the rest of the highlights from Dr. Berrocal and Dr. Kupperman. #retina Retina World Congress Healio | Ocular Surgery News Vindico Medical Education #retinaworldcongress Financial Disclosures: Dr. Berrocal and Dr. Kuppermann are consultants for Genentech 

Dear Colleagues, A recent publication in Medical Science Monitor explores the efficacy of percutaneous coronary intervention (PCI) in patients with multi-vessel coronary artery disease (MVD) and moderate/severe ischemic mitral regurgitation (IMR). The study found that PCI could significantly improve MR severity without mitral valve intervention, offering a potential alternative for elderly patients with low body weight and renal insufficiency. These findings highlight the potential of PCI to spare high-risk surgery and alleviate the burden of IMR in specific patient populations. The complete report is now available on the Medical Science Monitor webpage. | https://lnkd.in/ds2YUC9u

💥 Persistent patent bilateral occipital sinus 💥 • It is a very rare condition • Very much challenging for surgeons operating for post fossa tumors • Proper study of Pre op venous anatomy will avoid morbidity and mortality • Usually associated with aplastic, absent or hypoplastic transverse sinus • A radiologist should be aware of persistent occipital sinus and its imaging features and should report patent sinuses in cases of posterior fossa abnormalities. This guides crucial modification of surgical planning during the posterior fossa approach of surgical procedure and avoids catastrophic bleeding, brain swelling and neurosurgical morbidity due to sinus injury. This 👇66 years old female diagnosed with fourth ventricular ependymoma extending up to C2 underwent sub occipital craniotomy and complete excision During Dural opening torrential bleeding from the occipital sinus encountered which was controlled with Liga clips. After double ligation and dividing right occipital sinus encountered which, tumour was reached and excised completely. Dr Venkatesan MCh MIOT International

 📣 New publication!!! 📢 I'm thrilled to announce that our team, led by Dr. José F. Alfonso, has just published a groundbreaking study in an special issue in the Journal of Clinical Medicine on a brand-new surgical technique: Pseudochamber-Protected Keratoplasty (PPK) using the Endo-K Pro® implant. ⬆ This innovative approach is designed for high-risk cases of penetrating keratoplasty, providing a safer, closed-system alternative for full-thickness corneal transplants. 👀 👁️✨ With a focus on improving graft survival and minimizing complications, the PPK technique using the Endo-K Pro® implant offers an exciting option for surgeons managing complex cases. 👁️✨Our results show promising outcomes, and we believe this advancement could transform the approach to corneal transplantation in high-risk patients. #Ophthalmology #CornealTransplantation #Innovation #endok #SurgicalTechniques #EyeHealth #Research #MedicalAdvances 👁️🗨️ Check out the full article and dive into the details of our findings: 👇 👇 👇